Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery

DISEASE CHARACTERISTICS: * Pathologically proven non-small cell lung cancer (NSCLC) * Stage IA-IIIB disease * Underwent prior complete surgical resection (R0) no more than 2 months ago * Eligible for cisplatin-based adjuvant chemotherapy PATIENT CHARACTERISTICS: * Karnofsky performance status ≥ 70% * Absolute neutrophil count ≥ 1,500/mm\^3 * Hemoglobin ≥ 8.0 g/dL * Platelet count ≥ 100,000/mm\^3 * Creatinine clearance \> 55 mL/min * Total bilirubin normal * Alkaline phosphatase, AST, and ALT must meet 1 of the following criteria: * Alkaline phosphatase (AP) normal AND AST and ALT ≤ 5 times upper limit of normal (ULN) * AP ≤ 2.5 times ULN AND AST and ALT ≤ 1.5 times ULN * AP ≤ 5 times ULN AND AST and ALT normal * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after completion of study treatment * No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80 * No peripheral neuropathy \> grade 1 * No hearing deficit at baseline, even if it does not require a hearing aid or intervention or interfere with activities of daily life (i.e., CTCAE grade 2 or higher) PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior postoperative radiation therapy * No prior chemotherapy for NSCLC * No prior docetaxel or cisplatin * No concurrent prophylactic filgrastim (G-CSF) or pegfilgrastim